Idenix Pharmaceuticals Selected to Join the NASDAQ Biotechnology Index
16 May 2005 - 11:30PM
PR Newswire (US)
Idenix Pharmaceuticals Selected to Join the NASDAQ Biotechnology
Index CAMBRIDGE, Mass., May 16 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company
engaged in the discovery, development and commercialization of
drugs for the treatment of human viral and other infectious
diseases, today announced that it has been selected to join the
NASDAQ Biotechnology Index, effective with the market open on May
23, 2005. Launched in 1993, the NASDAQ Biotechnology Index includes
pharmaceutical and biotechnology companies as classified by the
FTSE(TM) Global Classification System. The Index is ranked on a
semi-annual basis in May and November and serves as the basis for
the iShares NASDAQ Biotechnology Index Fund(SM) (AMEX:IBB). All
securities in the NASDAQ Biotechnology Index are listed on the
NASDAQ National Market and meet minimum requirements including
market value, average daily share volume, and seasoning as a public
company among other criteria. For more information about the NASDAQ
Biotechnology Index, including eligibility criteria, visit
http://www.nasdaq.com/. About Idenix Idenix Pharmaceuticals, Inc.
(NASDAQ:IDIX) is a biopharmaceutical company engaged in the
discovery, development and commercialization of drugs for the
treatment of human viral and other infectious diseases. Idenix's
current focus is on the treatment of infections caused by hepatitis
B virus, hepatitis C virus and human immunodeficiency virus (HIV).
Idenix's headquarters are located in Cambridge, Massachusetts. The
company also has drug discovery and development operations in
Montpellier, France and drug discovery operations in Cagliari,
Italy. For further information about Idenix, please refer to
http://www.idenix.com/. Forward-looking Statements This press
release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. Statements in
this press release other than those that are historical in nature
are "forward-looking statements." Forward looking statements, which
include statements with respect to the potential therapeutic
benefits and successful development of the company's product
candidates and the company's drug discovery and research,
regulatory approval processes and commercialization activities, are
subject to numerous factors, risks and uncertainties that may cause
actual events or results to differ materially from the company's
current expectations. These risks and uncertainties relate to the
results of clinical trials and other studies with respect to the
product candidates that the company has under development; the
timing and success of submission, acceptance and approval of
regulatory filings; the company's dependence on its collaboration
with Novartis Pharma AG; the company's ability to obtain additional
funding required to conduct its research, development and
commercialization activities; the ability of the company to attract
and retain qualified personnel and the company's ability to obtain,
maintain and enforce patent and other intellectual property
protection for its product candidates and its discoveries. These
and other risks are described in greater detail under the caption
"Factors That May Affect Future Results" in Item 7 of the company's
quarterly report on Form 10-Q for the quarter ended March 31, 2005
and filed with the Securities and Exchange Commission and other
filings that the company makes with the Securities and Exchange
Commission. All forward-looking statements reflect the company's
expectations only as of the date of this release and should not be
relied upon as reflecting the company's views, expectations or
beliefs at any date subsequent to the date of this release. Idenix
anticipates that subsequent events and developments may cause these
views, expectations and beliefs to change. However, while Idenix
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
Contact: Idenix Pharmaceuticals, Inc. Media: Teri Dahlman (617)
995-9905 Investors: Amy Sullivan (617) 995-9838 DATASOURCE: Idenix
Pharmaceuticals, Inc. CONTACT: Teri Dahlman, Media,
+1-617-995-9905, or Amy Sullivan, Investors, +1-617-995-9838, both
of Idenix Pharmaceuticals, Inc. Web site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More Idenix Pharmaceuticals (MM) News Articles